RT Journal Article
SR Electronic
T1 Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.08.20095471
DO 10.1101/2020.05.08.20095471
A1 Salazar, Eric
A1 Perez, Katherine K.
A1 Ashraf, Madiha
A1 Chen, Jian
A1 Castillo, Brian
A1 Christensen, Paul A.
A1 Eubank, Taryn
A1 Bernard, David W.
A1 Eagar, Todd N.
A1 Long, S. Wesley
A1 Subedi, Sishir
A1 Olsen, Randall J.
A1 Leveque, Christopher
A1 Schwartz, Mary R.
A1 Dey, Monisha
A1 Chavez-East, Cheryl
A1 Rogers, John
A1 Shehabeldin, Ahmed
A1 Joseph, David
A1 Williams, Guy
A1 Thomas, Karen
A1 Masud, Faisal
A1 Talley, Christina
A1 Dlouhy, Katharine G.
A1 Lopez, Bevin Valdez
A1 Hampton, Curt
A1 Lavinder, Jason
A1 Gollihar, Jimmy D.
A1 Maranhao, Andre C.
A1 Ippolito, Gregory C.
A1 Saavedra, Matthew Ojeda
A1 Cantu, Concepcion C.
A1 Yerramilli, Prasanti
A1 Pruitt, Layne
A1 Musser, James M.
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.05.08.20095471.abstract
AB Background COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally, and no proven treatments are available. Convalescent plasma therapy has been used with varying degrees of success to treat severe microbial infections for more than 100 years.Methods Patients (n=25) with severe and/or life-threatening COVID-19 disease were enrolled at the Houston Methodist hospitals from March 28 – April 14, 2020. Patients were transfused with convalescent plasma obtained from donors with confirmed SARS-CoV-2 infection and had been symptom free for 14 days. The primary study outcome was safety, and the secondary outcome was clinical status at day 14 post-transfusion. Clinical improvement was assessed based on a modified World Health Organization 6-point ordinal scale and laboratory parameters. Viral genome sequencing was performed on donor and recipient strains.Results At baseline, all patients were receiving supportive care, including anti-inflammatory and anti-viral treatments, and all patients were on oxygen support. At day 7 post-transfusion with convalescent plasma, nine patients had at least a 1-point improvement in clinical scale, and seven of those were discharged. By day 14 post-transfusion, 19 (76%) patients had at least a 1-point improvement in clinical status and 11 were discharged. No adverse events as a result of plasma transfusion were observed. The whole genome sequencing data did not identify a strain genotype-disease severity correlation.Conclusions The data indicate that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease. Randomized, controlled trials are needed to determine its efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institutes of Health grants AI146771-01 and AI139369-01, and the Fondren Foundation, Houston Methodist Hospital and Research Institute (to JMM). This research has been funded in whole or part with federal funds under a contract from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Contract Number 75N93019C00050 (to JL and GCI). A portion of this work was funded through Cooperative Agreement W911NF-12-1-0390 by the Army Research Office (to JDG).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no data availability issue.